ANN architecture. حسب Abdelfattah Dani (22226715)

ANN architecture and configuration. حسب Abdelfattah Dani (22226715)

Laser-Enhanced Bubble Detachment Velocity and Heat Dissipation on Abrasive Surfaces حسب Cong He (5074154)

الموضوعات:

Laser-Enhanced Bubble Detachment Velocity and Heat Dissipation on Abrasive Surfaces حسب Cong He (5074154)

الموضوعات:

Laser-Enhanced Bubble Detachment Velocity and Heat Dissipation on Abrasive Surfaces حسب Cong He (5074154)

الموضوعات:

Laser-Enhanced Bubble Detachment Velocity and Heat Dissipation on Abrasive Surfaces حسب Cong He (5074154)

الموضوعات:

Laser-Enhanced Bubble Detachment Velocity and Heat Dissipation on Abrasive Surfaces حسب Cong He (5074154)

الموضوعات:

Illustration of BSC control using ANN for WECS. حسب Abdelfattah Dani (22226715)

HSF2 reduced the decrease in the MMP in Caco-2 cells, which were observed by laser confocal microscopy. حسب Wen Wang (6570)

Performance comparison between the OTC-FOC and ANN-BSC. حسب Abdelfattah Dani (22226715)

Training process flowchart of ANN-based MPPT controller. حسب Abdelfattah Dani (22226715)

THD for the stator current i_sb (ANN-BSC). حسب Abdelfattah Dani (22226715)

ANN-BSC outcomes: (a) PMSG currents, (b) Zoom-in illustration. حسب Abdelfattah Dani (22226715)

Mean values and 95% confidence intervals for recovery time, Average NN Interval (AVNN); Standard Deviation of NN Intervals (SDNN), Low Frequency/ High Frequency Ratio (LF/HF); and... حسب Robert Trybulski (10998702)

Penalty conversions yield large practical decreases, but robustness and generalizability of result are limited by data quality and sample selection. حسب Ryan J. Treves (13527735)

Baseline patient characteristics across neutralizing monoclonal antibody trials. حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Quantitative antibody and antigen responses to nMAb vs placebo day 1-90: Pooled analysis of neutralizing monoclonal antibodies. حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for neutralizing monoclonal antibodies, among patients alive and with day 90 antibody and antigen measu... حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab. حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Antibody and antigen responses to Ensovibep vs placebo day 1–90. حسب Elizabeth S. Munroe (21568166)

الموضوعات: